Abstract Context Patient‐reported outcomes (PROs) are used in parallel with clinical
evidence to inform decisions made by industry, clinicians, regulators, health technology …

Surgery and radiotherapy, two locoregional cancer treatments, are essential to help improve
cancer outcomes, control, and palliation. The continued evolution in treatment processes …

The rapid development of immuno-oncology (IO) therapies for multiple types of cancer has
transformed the cancer treatment landscape and brightened the long-term outlook for many …

A quote attributed to Mark Twain states,“What gets us into trouble is not what we don't know.
It's what we know for sure that just ain't so.” The growing focus on patient centricity has …

Radiotherapy interventions are rapidly evolving and improving, holding promise for better
patient outcomes, yet at the possible detriment of higher societal costs. The ESTRO-HERO …

Background Headache disorders comprise the three most prevalent medical disorders
globally and contribute almost 20% to the total burden of neurologic illness. Although the …

Objectives Limitations in conventional cost-effectiveness methods have led to calls for
incorporation of additional value elements in assessments of health technologies. However …

Health technology assessments (HTAs) are meant to inform health policy by taking account
of all the potential impacts of using a health technology. In the 1990s, HTAs included …

PURPOSE Despite their impact on adherence in glaucoma, sociobehavioral factors may not
be adequately explored during clinical consultations. We aimed to elicit consensus between …

Purpose To ascertain renal cell carcinoma (RCC) financial toxicity on COVID-19 during the
COVID-19 crisis as patients are struggling with therapeutic and financial implications …